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Prehypertension remains an important public health challenge all over the world and appropriate treatments should be adopted
to prehypertensive group in diﬀerent degree eﬀectively. This review aimed to assess the prevalence of Prehypertension and provide
eﬀective evidence of the beneﬁts of treating prehypertensive patients. The reasonable evaluation and appropriate intervention of
prehypertensive remain need further study.
1.Introduction
Prehypertension was deﬁned as a systolic blood pressure of
120–139mmHg and/or a diastolic blood pressure of 80–
89mmHg. The concept of prehypertension was introduced
as the new guideline for the management of blood pressure
by the seventh report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JnC-7) [1]. The objectives of deﬁning this
classiﬁcation of blood pressure were to draw the clinical and
public healthy attention onthe prevention of people in this
range.Prehypertensionisaprecursorofclinicalhypertension
and is closely related with the increased incidence of cardio-
vascular disease [2–4]. Patients with Prehypertension (120–
139/80–89mmHg) have an increased risk of cardiovascular
morbidity and mortality compared with patients who have
normal blood pressure (<120/80mmHg). This paper aimed
to assess the prevalence of Prehypertension and provide
eﬀective evidence of the beneﬁts of treating prehypertensive
patients in community.
2. Epidemiology
2.1. High Prevalence of Prehypertension. The National Health
and Nutrition Examination Survey (NHANES) 1999-2000
reported that the overall prevalence of prehypertension was
31% all over the world, which was higher in men than
in women [5]. A statistical analysis of disease-free adult
NHANES participants which was conducted from 1999 to
2006 foundthatthe overallprevalenceofPreHTNindisease-
freeadultswas36.3%[6].TheATTICAstudywhichincluded
1514 men and 1528 women found that the prehypertensive
population was 39% (43% in men and 35% in women) [7].
The prevalence of prehypertension in India was found more
than 45% (of the 2,007 people studied, 47.4% had Prehy-
pertension and 34.7% had hypertension. Prehypertension
was found in 46.6% of the men and 49.8% of the women).
The data from Korean Nation Health and Nutrition Survey
2001 reported that the estimated age-adjusted prevalence
of hypertension and prehypertension was 22.9% (26.9% in
men, 20.5% in women) and 31.6% (41.9% in men, 25.9% in
women [8]). The Jichi Medical School Cohort Study showed
that the prevalence of prehypertension was 34.8% (males)
and 31.8% (females) in Japanese general population [9].
Cross-sectional surveys of Shandong and Wuhan Provinces
revealed that the prevalence of prehypertension was more
than 40% in China [10, 11].
2.2. Risk Factors. Prehypertension is correlated with the
recognized traditional cardiovascular risk factors such as
obesity, diabetes mellitus, and dyslipidemia. NHANES II
1999-2000 data showed that 64% of individuals with pre-
hypertension had at least another cardiovascular risk factor;
persons with Prehypertension were 1.65 times more likely
to have at least another adverse risk factor than those with
normotension and the percentage increased to 94% in those2 International Journal of Hypertension
aged60yearsorolder[12].Anothermortalitystudyofadults
aged 30–74 years at the time of the NHANES II examination
showed that almost 90% of individuals with prehypertension
had at least one other cardiovascular risk factor [13].
Many studies demonstrated that the prehypertensive group
had higher levels of blood glucose, total cholesterol, low-
density lipoprotein cholesterol, and triglycerides, higher
bodymassindex,andlowerlevelsofhigh-densitylipoprotein
cholesterol than the normotensive group [14, 15]. Obesity,
abnormalities of glucose metabolism, and insulin resistance
were the major factors associated with prehypertension
and hypertension [16]. BMI was a strong predictor of
prehypertension. The Jichi Medical School Cohort Study
which enrolled 4,706 males and 7,342 females of Japanese
general population suggested that body mass index (BMI)
of more than 23.0kg/m2 was the strongest determinant of
prehypertension [9]. Prehypertension was more prevalent
in diabetic than nondiabetic participants. Compared with
nondiabetic participants with normal blood pressure, the
hazard ratios of cardiovascular disease were higher for those
with both prehypertension and diabetes than for those with
prehypertension alone [17].
Other nontraditional cardiovascular risk factors had also
been relevant to the development of prehypertension. The
prevalence of metabolic syndrome in the prehypertension
group was higher than in the normal BP group. Larger
waist circumference and body mass index, higher levels of
triglycerides, fasting blood glucose, uric acid and ferritin,
and lower levels of high-density lipoprotein-cholesterol
were more common in subjects with prehypertension than
in those with normal BP [18]. Compared to normoten-
sives, prehypertension had higher C-reactive protein, tumor
necrosis factor-alpha, amyloid-a, homocysteine levels, and
higher white blood cell counts after correcting for multiple
comparisons and adjusting for age, body mass index, blood
lipids, glucose, food groups consumed, and other potential
confounders [19]. It was also found that the prevalence of
microalbuminuria in the prehypertension group was higher
than in the normal BP group [18]. The nationally represen-
tative sample of US adults among 5,827 participants without
cardiovascular disease (CVD) and hypertension concluded
that prehypertension was associated with higher serum
gamma-glutamyltransferase (GGT) levels [20]. In recent
years,people pay more attention to whetherprehypertension
causes change of myocardial structure and function. After
adjusting for intergroup diﬀerences in age, diabetes, body
mass index, smoking, study center, and plasma creatinine,
andmeanvaluesforleftventricular(LV)measurementswere
found to be signiﬁcantly increased in both the prehyper-
tensive and hypertensive groups compared with the normal
blood pressure group. LV systolic and diastolic function
diﬀered signiﬁcantly in the hypertensive groups, but not in
the prehypertensive participants, compared with the normal
blood pressure group [21]. It suggested that the LV structure
had been changed during prehypertension period; however,
the LV systolic and diastolic function had not been impacted
by the change.
2.3. Cardiovascular Disease and Prehypertension. Individu-
als with prehypertensive levels of blood pressure had an
increased risk of developing cardiovascular disease relative to
those with optimal levels. The association was pronounced
among individuals with diabetes mellitus, and among those
with high BMI [22]. It was also found that prehypertension
was associated with an increased risk for cardiovascular
disease, including myocardial infarction (MI) and coronary
artery disease (CAD), but no stroke, with a mean follow-
up period of 10 years [23]. The Jichi Medical School
Cohort Studys of Japan discovered that prehypertension was
associated with a 45% higher risk of cardiovascular events
than normal blood pressure after adjusting for traditional
cardiovascular risk factors. Prehypertension was associated
with an increased 10-year risk of cardiovascular disease; the
risk of cardiovascular events with prehypertension during
the second 5-year period was elevated in the nonelderly
subgroup (<65 years) [9]. A meta-analysis that included
approximately 1 million individuals from 61 long-term
epidemiological studies demonstrated that mortality from
ischemic heart disease and stroke in individuals aged 40–
89 years increased in a log-linear relationship together with
increases in both systolic/diastolic blood pressure. For each
20mmHg increase in systolic blood pressure or 10mmHg
increaseindiastolicbloodpressureover115/75mmHg,there
was a twofold increase in mortality associated with coronary
artery disease and stroke [24]. Longitudinal data from the
Framingham Heart study indicated that individuals formerly
classiﬁed as having “normal” and “high-normal” blood
pressure (120–139/80–89mmHg) were at increased risk
of developing full-blown hypertension and cardiovascular
disease later in life than those who had an optimal blood
pressure (<120/80mmHg) [25]. The study among 68,438
urban Chinese women aged 40–70years during an average of
5 years of followup showed that hypertension was associated
with high stroke mortality [26].
3. Treatment
3.1. Strategy of Treatment. The relationship between prehy-
pertension and cardiovascular disease aroused widespread
concern, and it became an important subject to prevent
and intervene. JNC-7 suggested the individuals of prehy-
pertension adopted a healthy lifestyle in order to lower
blood pressure and prevent progression to hypertension,
with associated reductions in target organ damage and
cardiovascularevents. 2007 ESH-ESC Practice Guidelines for
the Management of Arterial Hypertension emphasized that
cardiovascular complications of patients should immediately
take drug therapy to reduce the risk of cardiovascular events
even in the scope of prehypertensive [27].
3.2. Nonpharmacological Treatments. Prehypertensive blood
pressure levels identify individuals with elevated risk of
developing hypertension. Prehypertensive patients are not
the usual candidates for antihypertensive drug therapy, and
prehypertensive individuals should primarily be advised to
modify their lifestyle to lower their blood pressure to normalInternational Journal of Hypertension 3
values (systolic/diastolic blood pressure <120/80mmHg)
to reduce the risk of developing hypertension. Lifestyle
modiﬁcations were the main treatment recommended by
JNC-7 guidelines for the prehypertension patients. The
lifestyle modiﬁcations included (1) Lose weight, maintain
normal body weight, keep body mass index between 18.5
and 24.9kg/m2. (2) Adopt DASH eating plan, consume a
diet rich in fruits, vegetables, and low-fat dairy products
with a reduced content of saturated and total fat. (3) Adopt
dietary sodium reduction and reduce dietary sodium intake
no more than 100mmol per day (2.4g sodium or 6g
sodium chloride). (4) Promote physical activity. (5) Attempt
moderation of alcohol.
3.3. Dietary Approaches. It is known that obesity, sodium
intake, and alcohol consumption factors inﬂuence blood
pressure. The DASH diet is recommended by physicians
for people with hypertension (high blood pressure) or
prehypertension. The DASH diet eating plan has been
proven to lower blood pressure in studies sponsored by the
National Institutes of Health (Dietary Approaches to Stop
Hypertension). In addition to being a low-salt (or low-
sodium) plan, the DASH diet provides additional beneﬁts
to reduce blood pressure. It is based on an eating plan
rich in fruits and vegetables, and low-fat or nonfat dairy.
DASH dietary pattern is rich in potassium (from fruits
and vegetables) and calcium (from dairy), low in total and
saturated fat, and contains limited amounts of meats and
sweets [28]. Compared with a typical American control
diet, the DASH dietary pattern reduced SBP by 5.5mmHg
and DBP by 3.0mmHg overall. In the participants with
prehypertension, corresponding reductions were 3.5mmHg
and 2.1mmHg. It was also found that the reduction of
sodium intake levels below the current recommendation of
100mmol per day and the DASH diet both lower blood
pressure substantially, with greater eﬀects in combination
than singly. Long-term health beneﬁts will depend on the
ability of people to make long-lasting dietary changes and
the increased availability of lower-sodium foods [29].
3.4. Weight Reduction. Increased body weight is a strong
risk factor for prehypertension and weight loss is important
for the prevention and treatment of prehypertension and
hypertension. A lot of clinical trial data document the
signiﬁcant BP-lowering eﬀect of weight loss. A meta-analysis
of randomized controlled trials included twenty-ﬁve ran-
domized, controlled trials (comprising 34 strata) published
between 1966 and 2002 with a total of 4874 participants
was performed to estimate the eﬀect of weight reduction
on blood pressure overall and in population subgroups in
2003. Blood pressure reductions were −1.05mmHg (95%
CI, −1.43 to −0.66) systolic and −0.92mmHg (95% CI,
−1.28 to −0.55) diastolic when expressed per kilogram of
weight loss in this study. It was found that physical exercise
with weight reduction reduced blood pressure, decreased
cardiovascular risks, and improved abnormal left ventricular
relaxation recently [31].
3.5.SaltIntakeReduction. Manysurveysrevealtheconsistent
correlation between sodium intake and BP. Numerous trials
show that the limit of sodium intake leads to reductions in
BP [32, 33]. A long-term followup assessed 10–15 years after
the original trial at 10 clinic sites in 1987–90 (TOHP I) and
nine sites in 1990–5 (TOHP II) showed the remote eﬀects of
dietarysodiumreductionfor18months(TOHPI)orfor36–
48 months (TOHP II) on risk of cardiovascular disease. Risk
of a cardiovascular event was 25% lower among those in the
intervention group compared with the matched group after
adjusted for trial, clinic, age, race, and sex, and 30% lower
after further adjustment for baseline sodium excretion and
weight [34]. The study demonstrated that sodium reduction
could reduce long-term risk of cardiovascular events in
patients with prehypertension. However, it is diﬃcult to
maintain the reduction of sodium intake in the general
public.
3.6.PhysicalActivity. Thecorrelationbetweenhabitualphys-
ical activity and the development of hypertension have been
found in numerous studies. A meta-analysis demonstrated
the studies published and indexed between January 1966
and December 1998 concluded that progressive resistance
exercise was eﬃcacious for reducing resting systolic and
diastolic blood pressure in adults [35]. Another Meta-
analysis of randomized, controlled trials evaluated the eﬀect
of aerobic exercise on blood pressure. In the random-eﬀect
model, it was found that aerobic exercise was associated with
a signiﬁcant reduction in mean systolic and diastolic blood
pressure 3.84mmHg and 2.58mmHg, respectively [36]. A
study evaluated appropriate type and frequency of physical
activity for the beneﬁcial eﬀect on blood pressure among
Japanese male workers. There was a progressive reduction in
the hazards ratios of hypertension with increasing total daily
activity (hazards ratio of 0.65 in subjects who walked >8000
steps/day versus <4000 steps/day). Subjects who exercised
>3 times/week also showed a signiﬁcantly lower risk (0.35)
of developing hypertension versus those who exercised <3
times/week. In addition, accumulating intermittent bouts
of physical activity, as short as 10min, total 30min walk
sessions may reduce systolic BP in prehypertension.
3.7. Moderation of Alcohol. The recommendation of JNC-
7 suggested that the limit consumption to no more than 2
drinks (1oz or 30mL ethanol; e.g., 24oz beer, 10oz wine, or
3oz 80-proof whiskey) per day in most men and to no more
than 1 drink per day in women and lighter weight persons.
The regular consumption of alcohol elevates blood pressure
and the global estimates showed that the attributable risk
for hypertensive disease from alcohol was 16%. The increase
of blood pressure is approximately 1mmHg for each 10g
alcohol consumed and is largely reversible within 2–4 weeks
of abstinence or a substantial reduction in alcohol intake,
and this increase of blood pressure occurs irrespective of the
type of alcoholic beverage. Maximum cardiovascular beneﬁt
occursatrelativelylowlevelsofconsumption(i.e.,onetotwo
standard drinks a day in men (10–20g alcohol) and up to4 International Journal of Hypertension
one a day in women (10g alcohol)). In hypertensive subjects,
consumption beyond these levels would be unwise [37].
The reduction of blood pressure is always the compre-
hensive eﬀect of the lifestyle interventions in the manage-
ment of prehypertension. The main 6-month results from
the PREMIER trial showed that comprehensive behavioral
intervention programs improved blood pressure [38].
3.8. Pharmacological Treatments. Whether people without
diabetes or chronic kidney disease (CKD) should be given
pharmacological treatments or not is still on discussion
[39]. The pharmacological treatments could be used on
condition that lifestyle modiﬁcation trial fails to reduce
blood pressure to 130/80mmHg or less according to the
JNC-7 guidelines for prehypertension without diabetes or
chronic kidney disease (CKD) [1]. The trial of TROPHY
study evaluated the eﬀect of the angiotensin II receptor
antagonist candesartan cilexetil on the prevention of tran-
sition from prehypertension to stage 1 hypertension [40].
Participants were randomly assigned to receive two years of
candesartan (Atacand, AstraZeneca) or placebo, followed by
two years of placebo for all. When a participant reached
the study end point of stage 1 hypertension, treatment with
antihypertensive agents was initiated. Both the candesartan
group and the placebo group were instructed to make
changes in lifestyle to reduce blood pressure throughout
the trial. Over a period of four years, stage 1 hypertension
developed in nearly two thirds of patients with untreated
prehypertension, and the prehypertension treated with can-
desartan appeared to be well tolerated and reduced the risk
of incident hypertension during the study period. Another
study evaluated the impact of bovine casein hydrolysate
(c12Peptide) on prehypertension. After fourweeks, repeated
daily intake of 3.8g C12 peptide, the systolic, and diastolic
BP reduced signiﬁcantly by about 10 mmHg and 7mmHg,
respectively [41]. The drug intervention in patients with
prehypertension is therefore appealing. In the absence of
higher baseline risk, the absolute beneﬁt of treatment is
presumably small and was not demonstrated to date. These
individuals could be candidates to treatment with the aim
to prevent the development of full hypertension. The long-
lasting eﬀectiveness of nondrug therapies is low outside
the controlled conditions of randomized clinical trials,
and there is evidences that the use of BP-lowering drugs
reduces the incidence of hypertension in individuals with
prehypertension by more than 60%. Clinical trials testing the
eﬃcacy and safety of BP agents to prevent hypertension in a
population-based perspective are required. In the meantime,
it is worthy to present the option to start low doses of
BP agents for individuals with prehypertension without
comorbidities who do not respond to the prescription of
lifestyle modiﬁcation [42].
4. Conclusions
Thecategoryof“prehypertension”increasestheawarenessof
the high risk group of hypertension. Individuals with Prehy-
pertensionhaveanincreasedriskoffull-blownhypertension,
target organ damage, and cardiovascular-related morbidity
and mortality [43]. Despite progress in recent years in the
prevention, detection, and treatment of Prehypertension, it
remains an important public health challenge that adopts
appropriate treatments to prehypertensive group in diﬀerent
degrees eﬀectively. The reasonable evaluation and appropri-
ate intervention of prehypertensive need further study.
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